Epic Aims to ‘Revolutionize Cancer Care'
Epic Sciences' pitch: greater certainty. The company's portfolio of tests guide cancer doctors deciding on a treatment path, including a test on the market for advanced prostate cancer. Epic recently hauled in a $52 million Series E round, making the privately held company well capitalized for the foreseeable future, according to CEO Murali Prahalad. Eventually, the San Diego-based company may look at an initial public offering, he said.